Goldman Sachs Upgrades Las Vegas Sands (LVS) to Buy
Get Alerts LVS Hot Sheet
Price: $46.56 --0%
Rating Summary:
27 Buy, 12 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 8 | New: 11
Rating Summary:
27 Buy, 12 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 8 | New: 11
Join SI Premium – FREE
Goldman Sachs upgraded Las Vegas Sands (NYSE: LVS) from Neutral to Buy with a price target of $52, suggesting 13% upside.
The analyst said "attractive geographic position (highest exposure to Asia), "same-store" sales and unit growth potential, strong balance sheet, and compelling valuation make LVS one of the most attractive stocks in our coverage universe."
Catalyst include: a generally upbeat analyst day on September 21; bullish
monthly stats out of Macau and Las Vegas, along with positive commentary out of Singapore; the potential for dividend activity; the phased opening of Sites 5 and 6; news about new market opportunities in Asia.
For more ratings news on Las Vegas Sands click here and for the rating history of Las Vegas Sands click here.
Shares of Las Vegas Sands closed at $45.85 yesterday.
The analyst said "attractive geographic position (highest exposure to Asia), "same-store" sales and unit growth potential, strong balance sheet, and compelling valuation make LVS one of the most attractive stocks in our coverage universe."
Catalyst include: a generally upbeat analyst day on September 21; bullish
monthly stats out of Macau and Las Vegas, along with positive commentary out of Singapore; the potential for dividend activity; the phased opening of Sites 5 and 6; news about new market opportunities in Asia.
For more ratings news on Las Vegas Sands click here and for the rating history of Las Vegas Sands click here.
Shares of Las Vegas Sands closed at $45.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Upgrades First Solar (FSLR) to Outperform
- Morgan Stanley Double Downgrades AU Optronics (2409:TT) (AUO) to Underweight
- JPMorgan Upgrades CytomX Therapeutics (CTMX) to Neutral, 'Entering a Catalyst Rich Period'
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Goldman Sachs, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!